CN110215455A - A kind of pharmaceutical formulation for blood pressure lowering - Google Patents
A kind of pharmaceutical formulation for blood pressure lowering Download PDFInfo
- Publication number
- CN110215455A CN110215455A CN201910232190.2A CN201910232190A CN110215455A CN 110215455 A CN110215455 A CN 110215455A CN 201910232190 A CN201910232190 A CN 201910232190A CN 110215455 A CN110215455 A CN 110215455A
- Authority
- CN
- China
- Prior art keywords
- blood pressure
- pharmaceutical formulation
- amlodipine
- pressure lowering
- losartan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a kind of pharmaceutical formulation for blood pressure lowering, belongs to field of pharmaceutical formulations.It is characterized in that according to parts by weight, including 1 part of Amlodipine (5mg), 1 part of Losartan Potassium (50mg).It is mainly used for treating essential hypertension, the patient of blood pressure cannot be sufficiently controlled for single therapy.It is better than conventional buck medicine, has the characteristics that the monolithic compound preparation of optimization while realizing collaboration decompression, uric acid of patient level is effectively reduced, can also reduce adverse reaction.Losartan/Amlodipine monolithic compound preparation is below the exclusive use of Losartan (ARB) and Amlodipine (CCB) in terms of the incidence of various adverse reactions.
Description
Technical field
The invention belongs to field of pharmaceutical formulations, relate in particular to a kind of pharmaceutical formulation for blood pressure lowering.
Background technique
Hypertension is cerebral apoplexy, myocardial infarction, the important risk factor of heart failure and chronic kidney disease, and hypertension is annual
The death caused by the whole world is more than 7,000,000, it has also become the mankind occupy the dead disease of leading position.
Losartan Amlodipine is ARB/CCB monolithic compound preparation, combines extensive two kinds of clinical application in the world and resists
Hypertension drug-Losartan (angiotensin receptor antagonist, ARB) and Amlodipine (calcium ion channel blocker, CCB).
It treats essential hypertension, and the patient of blood pressure cannot be sufficiently controlled for single therapy.Better than conventional buck medicine, there is optimization
The monolithic compound preparation of feature can also reduce adverse reaction while realizing collaboration decompression.Discussion shows Losartan/ammonia
The monolithic compound preparation of Flordipine is below Losartan (ARB) and Amlodipine in terms of the incidence of various adverse reactions
(CCB) exclusive use.
It is obvious that Losartan reduces blood uric acid effect.Compared to the combination of diuretics, Losartan/Amlodipine compound preparation can
Be substantially reduced cardiovascular event incidence, Olivetti cardiac studies to 547 middle-aged male follow-up 12 years, find blood urine sour water
Every increase 59.5umol/l is put down, hypertension incidence relative risk increases by 25%.Framingham research to 3329 healthy persons with
It visits 4 years, discovery uric acid is the independent predictor of hypertension incidence and long-term blood pressure.In the 1980s, Sino-U.S.'s painstaking effort
Pipe epidemiology joint study, 1480 people of China normal arterial pressure a middle-aged person, follow-up 4 years, discovery: the every increase of male's uric acid level
1.14mg/dl, hypertension incidence relative risk increase by 1.4 times.Serum uric acid level be acute myocardial infarction AMI, cerebral apoplexy and institute intentionally
The independent hazard factor of vascular events.One classical basic research confirms the relationship of uric acid and blood pressure by animal experiment:
Rat makes serum uric acid level increase 1.6mg/dl within 7 weeks by inducer, and systolic pressure averagely increases 2.2mmHg.But if
Giving simultaneously reduces blood uric acid drug, and blood uric acid is normal, then blood pressure no longer increases, and prompts high lithemia related to blood pressure raising.
The present invention is a kind of with the significant drug for hypertension of good antihypertensive effect.
Summary of the invention
It is an object of the invention to: a kind of pharmaceutical formulation for blood pressure lowering
The technical solution adopted by the invention is as follows:
A kind of pharmaceutical formulation for blood pressure lowering, which is characterized in that according to parts by weight, including Amlodipine 5mg) 1 part,
1 part of Losartan Potassium (50mg).
Preferably, according to parts by weight, including 1 part of Amlodipine mesylate (5mg), 1 part of Losartan Potassium (50mg).
Specific embodiment
The present invention is embodied in the following manner, and the present invention is described further, these embodiments are only used for example
The purpose of card, is not intended to limit protection scope of the present invention.
A kind of pharmaceutical formulation for blood pressure lowering, it is characterised in that: the pharmaceutical formulation include according to parts by weight, including
Amlodipine 5mg) 1 part, 1 part of Losartan Potassium (50mg).
Above-mentioned formula Losartan Potassium 50g, Amlodipine Besylate Tablet 6.9g, superfine silica gel powder 1.5g, microcrystalline cellulose 62.9g,
Crospovidone 17g difference is finely ground, crosses 147 μm of sieves, is uniformly mixed with equal increments method, using water as binder, crosses 707 μm of sieve systems
Grain, the dry 2h at 60 DEG C, with magnesium stearate 1.7g is added after 841 μm of sieve whole grains, with the formed punch of 8mm, the pressure tabletting of 80N.
The above is only the preferred embodiment of the present invention, it should be pointed out that be above-mentioned preferred embodiment be not construed as to this
The limitation of invention, protection scope of the present invention should be defined by the scope defined by the claims..For the general of the art
For logical technical staff, without departing from the spirit and scope of the present invention, several improvements and modifications can also be made, these improvement
It also should be regarded as protection scope of the present invention with retouching.
Claims (9)
1. a kind of pharmaceutical formulation for blood pressure lowering, which is characterized in that according to parts by weight, including 1 part of Amlodipine (5mg),
1 part of Losartan Potassium (50mg).
2. a kind of pharmaceutical formulation of blood pressure lowering described in accordance with the claim 1, which is characterized in that according to parts by weight, including horse
Come sour 1 part of Amlodipine (5mg), 1 part of Losartan Potassium (50mg).
3. a kind of pharmaceutical formulation of blood pressure lowering described in accordance with the claim 1, which is characterized in that according to parts by weight, including first
1 part of sulfonic acid Amlodipine (5mg), 1 part of Losartan Potassium (50mg).
4. a kind of pharmaceutical formulation of blood pressure lowering described in accordance with the claim 1, which is characterized in that according to parts by weight, including benzene
1 part of sulfonic acid Amlodipine (5mg), 1 part of Losartan Potassium (50mg).
5. a kind of pharmaceutical formulation of blood pressure lowering described in accordance with the claim 1, which is characterized in that according to parts by weight, including door
1 part of aspartic acid Amlodipine (5mg), 1 part of Losartan Potassium (50mg).
6. a kind of pharmaceutical formulation of blood pressure lowering described in accordance with the claim 1, which is characterized in that according to parts by weight, including horse
Come sour 1 part of levamlodipine (5mg), 1 part of Losartan Potassium (50mg).
7. a kind of pharmaceutical formulation of blood pressure lowering described in accordance with the claim 1, which is characterized in that according to parts by weight, including first
1 part of sulfonic acid levamlodipine (5mg), 1 part of Losartan Potassium (50mg).
8. a kind of pharmaceutical formulation of blood pressure lowering described in accordance with the claim 1, which is characterized in that according to parts by weight, including benzene
1 part of sulfonic acid levamlodipine (5mg), 1 part of Losartan Potassium (50mg).
9. a kind of pharmaceutical formulation of blood pressure lowering described in accordance with the claim 1, which is characterized in that according to parts by weight, including door
1 part of aspartic acid levamlodipine (5mg), 1 part of Losartan Potassium (50mg).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910232190.2A CN110215455A (en) | 2019-03-26 | 2019-03-26 | A kind of pharmaceutical formulation for blood pressure lowering |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910232190.2A CN110215455A (en) | 2019-03-26 | 2019-03-26 | A kind of pharmaceutical formulation for blood pressure lowering |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110215455A true CN110215455A (en) | 2019-09-10 |
Family
ID=67822417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910232190.2A Pending CN110215455A (en) | 2019-03-26 | 2019-03-26 | A kind of pharmaceutical formulation for blood pressure lowering |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110215455A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112274490A (en) * | 2020-11-19 | 2021-01-29 | 四川尚锐生物医药有限公司 | Preparation method of amlodipine and losartan potassium compound composition |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101468002A (en) * | 2007-12-29 | 2009-07-01 | 北京瑞康医药技术有限公司 | Therapeutic composition containing amlodipine salt and losartan medicine |
| US20100233261A1 (en) * | 2006-12-08 | 2010-09-16 | Hanmi Pharm. Co., Ltd. | Pharmaceutical Composition Comprising Amlodipine and Losartan |
| CN101849940A (en) * | 2009-04-02 | 2010-10-06 | 鲁南制药集团股份有限公司 | Medicinal composition for treating hypertension |
| CN102335172A (en) * | 2011-07-20 | 2012-02-01 | 海南锦瑞制药股份有限公司 | Amlodipine and losartan potassium medicinal composition and preparation method thereof |
| CN103655561A (en) * | 2012-08-28 | 2014-03-26 | 海南中济医药科技有限公司 | Pharmaceutical composition containing losartan potassium and amlodipine besylate and preparation method thereof |
-
2019
- 2019-03-26 CN CN201910232190.2A patent/CN110215455A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100233261A1 (en) * | 2006-12-08 | 2010-09-16 | Hanmi Pharm. Co., Ltd. | Pharmaceutical Composition Comprising Amlodipine and Losartan |
| CN101468002A (en) * | 2007-12-29 | 2009-07-01 | 北京瑞康医药技术有限公司 | Therapeutic composition containing amlodipine salt and losartan medicine |
| CN101849940A (en) * | 2009-04-02 | 2010-10-06 | 鲁南制药集团股份有限公司 | Medicinal composition for treating hypertension |
| CN102335172A (en) * | 2011-07-20 | 2012-02-01 | 海南锦瑞制药股份有限公司 | Amlodipine and losartan potassium medicinal composition and preparation method thereof |
| CN103655561A (en) * | 2012-08-28 | 2014-03-26 | 海南中济医药科技有限公司 | Pharmaceutical composition containing losartan potassium and amlodipine besylate and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112274490A (en) * | 2020-11-19 | 2021-01-29 | 四川尚锐生物医药有限公司 | Preparation method of amlodipine and losartan potassium compound composition |
| CN112274490B (en) * | 2020-11-19 | 2022-11-22 | 四川尚锐生物医药有限公司 | Preparation method of amlodipine and losartan potassium compound composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101347427A (en) | Compound of losartan compound or its medical salt and calcium channel blocker or its medical salt | |
| JP2014098016A (en) | Pharmaceutical composition for treating hypertension and metabolic syndrome and application thereof | |
| TW200831078A (en) | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats | |
| WO2006034631A1 (en) | Composition comprising amlodipine and angiotensin ii receptor blocker | |
| CN110215455A (en) | A kind of pharmaceutical formulation for blood pressure lowering | |
| CN101632678B (en) | Losartan potassium hydrochlorothiazide composition and preparation method thereof | |
| KR101303841B1 (en) | Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof | |
| US20100168193A1 (en) | Therapeutic use of imidazole-5-carboxylic acid derivatives | |
| CN101134032A (en) | Compound preparations for treating hypertension and method for preparing the same | |
| Munger et al. | Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure | |
| US20160045497A1 (en) | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor | |
| JP2002145770A (en) | Pharmaceutical composition for prophylaxis or treatment of cardiac insufficiency | |
| CN104744404A (en) | Stable hydrochlorothiazide crystalline compound, and composite enalapril maleate pharmaceutical composition thereof | |
| US20120041035A1 (en) | Levamlodipine compound pharmaceutical composition | |
| CN101773500B (en) | Antihypertensive medicinal composition | |
| EP4360631A1 (en) | Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| CN101229156B (en) | Medicine composition used for cardiovascular disorders | |
| CN104758290A (en) | A compound antihypertensive composition and applications thereof | |
| CN101361736A (en) | Compound of losartan or pharmaceutical salt thereof and calcium channel blockers or pharmaceutical salt thereof | |
| CN102106853A (en) | Chemical medicine composition for treating hypertension | |
| CN113226374A (en) | Pharmaceutical composition containing amlodipine, chlorthalidone and aldosterone receptor antagonist | |
| CN101756974A (en) | Method for preparing antihypertensive preparation | |
| WO2020207355A1 (en) | Pharmaceutical composition containing amlodipine, chlorthalidone, and amiloride | |
| CN102552255A (en) | Amlodipine, aliskiren and sartan compound antihypertensive medicine | |
| CN102430109A (en) | Amlodipine, aliskiren and pril compound antihypertensive medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190910 |
|
| WD01 | Invention patent application deemed withdrawn after publication |